$PMVP
PMV Pharmaceuticals, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023040153 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.040M $6.279M $6.423M
YoY Change 5.8% -2.24% 19.25%
% of Gross Profit
Research & Development $13.59M $13.84M $11.46M
YoY Change -0.59% 20.77% 49.56%
% of Gross Profit
Depreciation & Amortization $358.0K $369.0K $82.00K
YoY Change 383.78% 350.0% 15.49%
% of Gross Profit
Operating Expenses $19.63M $20.12M $17.89M
YoY Change 1.31% 12.51% 37.05%
Operating Profit -$19.63M -$20.12M -$17.89M
YoY Change 1.31% 12.51% 37.05%
Interest Expense $2.980M $2.696M $604.0K
YoY Change 165.12% 346.36% 434.51%
% of Operating Profit
Other Income/Expense, Net $2.988M $2.690M $573.0K
YoY Change 162.8% 369.46% 225.57%
Pretax Income -$16.64M -$17.43M -$17.31M
YoY Change -8.76% 0.69% 34.47%
Income Tax $0.00 $4.000K -$2.000K
% Of Pretax Income
Net Earnings -$16.64M -$17.44M -$17.31M
YoY Change -8.72% 0.73% 34.46%
Net Earnings / Revenue
Basic Earnings Per Share -$0.34 -$0.38 -$0.38
Diluted Earnings Per Share -$0.34 -$0.38 -$379.8K
COMMON SHARES
Basic Shares Outstanding 48.45M 45.78M 45.57M
Diluted Shares Outstanding 49.05M 45.81M 45.57M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $238.1M $218.8M $277.4M
YoY Change -8.02% -21.12% -18.35%
Cash & Equivalents $52.06M $68.21M $87.09M
Short-Term Investments $186.0M $150.6M $190.3M
Other Short-Term Assets $3.400M $3.326M $4.431M
YoY Change -46.19% -24.94% -6.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $205.3M $190.4M $281.9M
YoY Change -22.58% -32.45% -12.76%
LONG-TERM ASSETS
Property, Plant & Equipment $10.82M $11.14M $8.721M
YoY Change 8.59% 27.69% 596.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $36.20M $31.76M $0.00
YoY Change -100.0%
Other Assets $180.0K $181.0K $308.0K
YoY Change -41.37% -41.23% 53.23%
Total Long-Term Assets $55.73M $51.80M $18.70M
YoY Change 181.36% 177.04% -43.04%
TOTAL ASSETS
Total Short-Term Assets $205.3M $190.4M $281.9M
Total Long-Term Assets $55.73M $51.80M $18.70M
Total Assets $261.0M $242.2M $300.6M
YoY Change -8.41% -19.41% -15.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.678M $3.489M $3.348M
YoY Change -65.23% 4.21% 41.33%
Accrued Expenses $9.038M $7.940M $7.652M
YoY Change 40.43% 3.76% 71.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.72M $11.45M $11.38M
YoY Change -8.06% 0.56% 51.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.70M $12.96M $12.21M
YoY Change 4.66% 6.13% 15.65%
Total Long-Term Liabilities $12.70M $12.96M $12.21M
YoY Change 4.66% 6.13% 15.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.72M $11.45M $11.38M
Total Long-Term Liabilities $12.70M $12.96M $12.21M
Total Liabilities $23.42M $24.41M $23.59M
YoY Change -1.58% 3.45% 30.62%
SHAREHOLDERS EQUITY
Retained Earnings -$294.2M -$277.6M -$203.5M
YoY Change 32.72% 36.44% 51.44%
Common Stock $532.2M $495.7M $481.5M
YoY Change 9.98% 2.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $237.6M $217.8M $277.0M
YoY Change
Total Liabilities & Shareholders Equity $261.0M $242.2M $300.6M
YoY Change -8.41% -19.41% -15.55%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$16.64M -$17.44M -$17.31M
YoY Change -8.72% 0.73% 34.46%
Depreciation, Depletion And Amortization $358.0K $369.0K $82.00K
YoY Change 383.78% 350.0% 15.49%
Cash From Operating Activities -$15.66M -$12.90M -$13.68M
YoY Change -6.56% -5.69% 47.96%
INVESTING ACTIVITIES
Capital Expenditures $50.00K $565.0K -$3.500M
YoY Change -102.44% -116.14% 651.07%
Acquisitions
YoY Change
Other Investing Activities -$33.59M -$63.40M -$11.78M
YoY Change -206.42% 438.23% 16.81%
Cash From Investing Activities -$33.64M -$63.96M -$15.28M
YoY Change -213.98% 318.63% 44.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.15M 2.131M 276.0K
YoY Change 552400.0% 672.1% -78.06%
NET CHANGE
Cash From Operating Activities -15.66M -12.90M -13.68M
Cash From Investing Activities -33.64M -63.96M -15.28M
Cash From Financing Activities 33.15M 2.131M 276.0K
Net Change In Cash -16.15M -74.73M -28.68M
YoY Change -226.57% 160.56% 54.73%
FREE CASH FLOW
Cash From Operating Activities -$15.66M -$12.90M -$13.68M
Capital Expenditures $50.00K $565.0K -$3.500M
Free Cash Flow -$15.71M -$13.47M -$10.18M
YoY Change 6.81% 32.29% 15.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001699382
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39539
dei Entity Registrant Name
EntityRegistrantName
PMV PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3218129
dei Entity Address Address Line1
EntityAddressAddressLine1
One Research Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Princeton
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08540
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
642-6670
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
dei Trading Symbol
TradingSymbol
PMVP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48454582
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68209000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
108297000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
822000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
822000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
118878000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
132757000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2504000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5130000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
190413000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
247006000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11136000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10955000
CY2023Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
31757000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2495000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8729000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9539000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
181000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
313000
CY2023Q2 us-gaap Assets
Assets
242216000
CY2022Q4 us-gaap Assets
Assets
270308000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3489000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2996000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7940000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7308000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11447000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10832000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12960000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13448000
CY2023Q2 us-gaap Liabilities
Liabilities
24407000
CY2022Q4 us-gaap Liabilities
Liabilities
24280000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46143536
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46143536
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45771332
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45771332
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
495744000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
487516000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277607000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-241043000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-328000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-445000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
217809000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
246028000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
242216000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
270308000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13843000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11462000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28916000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23297000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6279000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6423000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12686000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13206000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
20122000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
17885000
us-gaap Operating Expenses
OperatingExpenses
41602000
us-gaap Operating Expenses
OperatingExpenses
36503000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20122000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17885000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41602000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36503000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2696000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
604000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5022000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
832000
CY2023Q2 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-6000
CY2022Q2 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-31000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
20000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-72000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2690000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
573000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5042000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
760000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17432000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17312000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36560000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35743000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17436000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
us-gaap Net Income Loss
NetIncomeLoss
-36564000
us-gaap Net Income Loss
NetIncomeLoss
-35743000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-212000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-357000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
117000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-945000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17648000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17667000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36447000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36688000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45813132
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45813132
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45571067
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45571067
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45793355
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45793355
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45518845
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45518845
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
308559000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2177000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-18433000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-588000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
291843000
CY2022Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
276000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2518000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17310000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-357000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
276970000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
246028000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2932000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-19128000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
329000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
230173000
CY2023Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
105000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2026000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3153000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17436000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-212000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
217809000
us-gaap Profit Loss
ProfitLoss
-36564000
us-gaap Profit Loss
ProfitLoss
-35743000
us-gaap Share Based Compensation
ShareBasedCompensation
6085000
us-gaap Share Based Compensation
ShareBasedCompensation
4695000
us-gaap Depreciation
Depreciation
540000
us-gaap Depreciation
Depreciation
166000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1669000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-126000
pmvp Other Non Cash Lease Income Expense
OtherNonCashLeaseIncomeExpense
188000
pmvp Other Non Cash Lease Income Expense
OtherNonCashLeaseIncomeExpense
-180000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
88000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2758000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
308000
pmvp Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-1612000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
493000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1342000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
632000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-975000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27913000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31677000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
721000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4296000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
129552000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
149223000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
115955000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
99415000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14318000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54104000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2026000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
117000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
404000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2143000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
404000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40088000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-85377000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109119000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
173289000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69031000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87912000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1501000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17436000
us-gaap Net Income Loss
NetIncomeLoss
-36564000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27913000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277607000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
218844000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, research and development costs, accrued research and development costs and related prepaid expenses and stock-based compensation. Actual results could differ materially from those estimates.</span></p>
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
1670000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
126000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
822000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
822000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
215655000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
328000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215327000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
242558000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
21000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
466000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
242113000
CY2023Q2 us-gaap Cash
Cash
3517000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
64692000
CY2022Q4 us-gaap Cash
Cash
1436000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
106861000
CY2023Q2 us-gaap Marketable Securities
MarketableSecurities
150635000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
118878000
CY2023Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
31757000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
135252000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
132757000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2495000
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13860000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13139000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2724000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2184000
us-gaap Operating Lease Cost
OperatingLeaseCost
1042000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
311000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11136000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10955000
CY2023Q2 us-gaap Depreciation
Depreciation
369000
CY2022Q2 us-gaap Depreciation
Depreciation
82000
us-gaap Depreciation
Depreciation
540000
us-gaap Depreciation
Depreciation
166000
CY2023Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2717000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2897000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
357000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
152000
CY2023Q2 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4866000
CY2022Q4 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4259000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7940000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7308000
CY2018Q3 pmvp Number Of Noncancelable Operating Leases
NumberOfNoncancelableOperatingLeases
2
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
596000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
530000
us-gaap Operating Lease Cost
OperatingLeaseCost
1193000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
198000
us-gaap Variable Lease Cost
VariableLeaseCost
630000
us-gaap Variable Lease Cost
VariableLeaseCost
395000
CY2023Q2 us-gaap Lease Cost
LeaseCost
907000
CY2022Q2 us-gaap Lease Cost
LeaseCost
728000
us-gaap Lease Cost
LeaseCost
1823000
us-gaap Lease Cost
LeaseCost
1437000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8729000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9539000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
528000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12960000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13448000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12978000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
13976000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y29D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
pmvp Net Cash Paid Received For Amounts Included In The Measurement Of Lease Liabilities
NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
1382000
pmvp Net Cash Paid Received For Amounts Included In The Measurement Of Lease Liabilities
NetCashPaidReceivedForAmountsIncludedInTheMeasurementOfLeaseLiabilities
-750000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10000
CY2023Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsRemainderOfFiscalYear
-175000
CY2023Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths
1814000
CY2023Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo
1869000
CY2023Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree
1925000
CY2023Q2 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour
1983000
CY2023Q2 pmvp Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Four
LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFour
9494000
CY2023Q2 pmvp Lessee Operating Lease Liability Payments Net Of Repayments Due
LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue
16910000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3932000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12978000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
596000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
530000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1193000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1042000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46143536
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46143536
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45771332
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45771332
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
457713
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4618292
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5278771
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.40
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17244000
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Reserved For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesReservedForIssuance
1830853
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
1882125
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1882125
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.76
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
28251
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
28251
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.89
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7733
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.55
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4595271
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7124912
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M7D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11010000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7124912
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3153000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M7D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
11010000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3839622
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M4D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9533000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
27617000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0345
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0395
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0148
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0293
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
374899
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.6
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
374899
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.6
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3153000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2518000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6085000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4695000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2518000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6085000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4695000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7563598
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5378322

Files In Submission

Name View Source Status
0000950170-23-040153-index-headers.html Edgar Link pending
0000950170-23-040153-index.html Edgar Link pending
0000950170-23-040153.txt Edgar Link pending
0000950170-23-040153-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmvp-20230630.htm Edgar Link pending
pmvp-20230630.xsd Edgar Link pending
pmvp-ex31_1.htm Edgar Link pending
pmvp-ex31_2.htm Edgar Link pending
pmvp-20230630_def.xml Edgar Link unprocessable
pmvp-20230630_lab.xml Edgar Link unprocessable
pmvp-20230630_pre.xml Edgar Link unprocessable
pmvp-20230630_htm.xml Edgar Link completed
pmvp-ex32_1.htm Edgar Link pending
pmvp-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pmvp-20230630_cal.xml Edgar Link unprocessable